Johnson & Johnson $JNJ is Cullinan Associates Inc.’s 5th Largest Position

Cullinan Associates Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 5.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 183,038 shares of the company’s stock after selling 11,067 shares during the period. Johnson & Johnson accounts for approximately 3.6% of Cullinan Associates Inc.’s portfolio, making the stock its 5th largest holding. Cullinan Associates Inc.’s holdings in Johnson & Johnson were worth $44,742,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Blueline Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $25,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the fourth quarter worth $26,000. DecisionPoint Financial LLC raised its holdings in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares during the last quarter. Family CFO Inc acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC lifted its position in shares of Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 15th. Johnson Rice set a $270.00 target price on shares of Johnson & Johnson in a report on Friday, June 26th. Barclays lifted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Finally, Raymond James Financial raised their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $261.26.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $257.82 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The company has a market cap of $620.64 billion, a P/E ratio of 29.81, a P/E/G ratio of 2.51 and a beta of 0.24. Johnson & Johnson has a fifty-two week low of $154.80 and a fifty-two week high of $269.43. The firm’s 50 day moving average is $237.62 and its two-hundred day moving average is $233.60.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.77 EPS. Analysts expect that Johnson & Johnson will post 11.58 EPS for the current year.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on Johnson & Johnson (JNJ) to $287 from $265 and kept an outperform rating, implying additional upside as investors look ahead to earnings. Benzinga
• Positive Sentiment: Several market watchers highlighted JNJ as a potential buy before earnings, pointing to its strong year-to-date move, recent all-time highs, and the appeal of its dividend as capital rotates into healthcare names. The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
• Positive Sentiment: Analysts and stock commentary remain focused on JNJ’s upcoming quarterly results, with expectations centered on continued operational strength despite patent and competitive headwinds. Zacks: Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
• Neutral Sentiment: Broader market weakness weighed on Wall Street Monday, which could limit gains even for defensive names like JNJ. NASDAQ Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran Tensions
• Neutral Sentiment: Pre-earnings previews from Zacks, TipRanks, and Barron’s kept Johnson & Johnson in focus, but these pieces were mainly commentary ahead of the report rather than new company-specific catalysts. Zacks: Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.